Unique ID issued by UMIN | UMIN000007540 |
---|---|
Receipt number | R000008909 |
Scientific Title | Small intestinal mucosal adaptation in the long-term administration of a NSAID and the efficacy of irsogladine maleate, a gastroprotective drug, and omeprazole in healthy volunteers: a prospective randomized trial |
Date of disclosure of the study information | 2012/03/21 |
Last modified on | 2012/10/02 10:44:43 |
Small intestinal mucosal adaptation in the long-term administration of a NSAID and the efficacy of irsogladine maleate, a gastroprotective drug, and omeprazole in healthy volunteers: a prospective randomized trial
Comparison of the Efficacy of Irsogladine and Omeprazole Against NSAIDs-Induced Small Intestinal Lesions
Small intestinal mucosal adaptation in the long-term administration of a NSAID and the efficacy of irsogladine maleate, a gastroprotective drug, and omeprazole in healthy volunteers: a prospective randomized trial
Comparison of the Efficacy of Irsogladine and Omeprazole Against NSAIDs-Induced Small Intestinal Lesions
Japan |
NSAID induced small intestinal lesions
Gastroenterology |
Others
NO
We investigate whether a continuous NSAID administration cause further damage or not and the efficacy of irsogladine and omeprazole on such lesions.
Efficacy
Exploratory
Phase IV
The number of small intestinal mucosal breaks evaluated in the capsule endoscope.
1. fecal calprotectin
2. hemoglobin
3. occult fecal blood test
Interventional
Parallel
Randomized
Open -but assessor(s) are blinded
No treatment
3
Prevention
Medicine |
irsogladine 4mg/day and dicrofenacNa75mg/day for 6weeks in oral administration
omeprazole 10mg/day and dicrofenacNa75mg/day for 6weeks in oral administration
After that omeprazole 10mg/day, dicrofenacNa75mg/day and irsogladine 4mg/day for another 4weeks in oral administration
omeprazole 10mg/day and dicrofenacNa75mg/day for 10weeks in oral administration
20 | years-old | <= |
80 | years-old | > |
Male and Female
1) Healthy adults who are 20 years or older, and less than 80 years of age at the time of obtaining
consent
2) Subjects from whom fully informed written consent based on their full understanding and their
own voluntary will was obtained when participating this study
1) Subjects with a history of peptic ulcer or gastrointestinal bleeding
2) Subjects with significant hepatic disease, renal disease, heart disease, or respiratory disease
3) Subjects with a history of gastrointestinal surgery other than appendectomy
4) Subjects orally taking or planning to orally take drug other than antiulcer drug or NSAIDs
5) Subjects with alcohol or chemical dependencies
6) Subjects with a history of intestinal obstruction, or person with suspected gastrointestinal
obstruction on other tests
7)Subjects who cannot agree that surgery may be required if capsule endoscope retained in the body
8) Subjects whom otherwise the investigator determined ineligible as the subject
37
1st name | |
Middle name | |
Last name | Kazuhide Higuchi |
Osaka Medical College
Second Department of Internal Medicine
2-7 Daigakumachi Takatsuki Osaka 569-8686 Japan
1st name | |
Middle name | |
Last name |
Osaka Medical College
Second Department of Internal Medicine
Second Department of Internal Medicine, Osaka Medical College
Second Department of Internal Medicine, Osaka Medical College
Self funding
NO
2012 | Year | 03 | Month | 21 | Day |
Unpublished
Completed
2010 | Year | 03 | Month | 01 | Day |
2010 | Year | 04 | Month | 01 | Day |
2012 | Year | 03 | Month | 21 | Day |
2012 | Year | 10 | Month | 02 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000008909